All In Biotech

Drug Trial Radar · NCT07935291

Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults

A Phase Ⅰ Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Weight-Loss Effect of IPG1094 Tablets in Chinese Healthy Adults and Obese Adult Participants

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Nov 25, 2026

Primary completion

Jun 25, 2027

Study completion Aug 25, 2027

Sponsor

Sponsor type
Industry
Collaborators
Zhejiang Hospital
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary weight-loss effect of IPG1094 tablets. The study includes three parts: Part A is single ascending dose in healthy volunteers; Part B is multiple ascending dose in healthy volunteers; Part C is multiple-dose exploration in obese adult participants. Subjects will be randomly assigned to receive IPG1094 or matching placebo. Safety, blood drug concentration and weight-related indicators will be followed up.

Conditions

  • Healthy Volunteers; Obesity

Interventions

  • IPG1094 Tablet and matching PlaceboDrug

    IPG1094 tablet is a macrophage migration inhibitory factor(MIF) modulator tablet; matching placebo identical in appearance, dosage form and number of tablets. Part A: single oral dose under fasting condition. Part B: multiple oral doses after standard meal; B1-B3 QD ×10 d; optional B4: BID ×9 d, morning dose only on Day10. Part C: obese participants take drug after standard breakfast; C1/C2 28-day QD; C3 90-day QD; D-1-D10 in-hospital; subsequent home administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
  2. Part A: Time to Maximum Plasma Concentration (Tmax) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
  3. Part A: Terminal Elimination Half-life (t1/2) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
  4. Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
  5. Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
  6. Part A: Apparent Oral Clearance (CL/F) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
  7. Steady-State Maximum Observed Plasma Concentration (Css,max) of IPG1094 in Part BTime frame: Day 1 to Day 13
  8. Time to Steady-State Maximum Plasma Concentration (Tss,max) of IPG1094 in Part BTime frame: Day 1 to Day 13
  9. Area Under the Plasma Concentration-Time Curve Over One Dosing Interval at Steady State (AUC0-τ) of IPG1094 in Part BTime frame: Day 1 to Day 13
  10. Steady-State Apparent Oral Clearance (CLss/F) of IPG1094 in Part BTime frame: Day 1 to Day 13
  11. Accumulation Index Based on AUC (Rac,AUC) of IPG1094 in Part BTime frame: Day 1 to Day 13
  12. Accumulation Index Based on Cmax (Rac,Cmax) of IPG1094 in Part BTime frame: Day 1 to Day 13
  13. Safety indicators:adverse eventTime frame: Day30 for 100/200 mg QD groups;Day90 for 300 mg QD group

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.